Laboratory indicators combined with liver function scores for predicting suboptimal hepatobiliary phase imaging during gadoxetic acid-enhanced MRI
- 1Department of Medical Imaging, Guangxi Medical University Cancer Hospital, Nanning, China
Abstract
Background: Suboptimal hepatobiliary-phase (HBP) enhancement may limit the diagnostic quality of gadoxetic acid-enhanced MRI. We investigated whether routinely available laboratory indicators and liver function scores could identify patients at increased risk of suboptimal HBP imaging.
Methods: This retrospective study included 555 patients with focal liver lesions who underwent gadoxetic acid-enhanced MRI, including 460 with good and 95 with suboptimal HBP image quality. Associations between laboratory indicators, liver function scores, and HBP image quality were evaluated using correlation and logistic regression analyses. Model discrimination, calibration, internal validation, and potential clinical utility were assessed using ROC analysis, bootstrap resampling, calibration analysis, and decision-curve analysis.
Results: The ALBI score (OR=2.391, 95% CI: 1.364–4.190), GGT (OR=1.003, 95% CI: 1.001–1.004), TBA (OR=1.010, 95% CI: 1.003–1.017), and Hb (OR=0.982, 95% CI: 0.971–0.993) were independently associated with suboptimal HBP imaging. The combined model yielded an AUC of 0.758 (95% CI: 0.701–0.816), with 63.16% sensitivity and 78.70% specificity. Bootstrap internal validation that repeated the entire model-development procedure yielded a mean AUC optimism of 0.044 and an optimism-corrected AUC of 0.714, indicating that moderate discrimination was retained after correction for model-development optimism. The apparent and optimism-corrected Brier scores were 0.116 and 0.128, respectively.
Conclusions: A model combining the ALBI score, GGT, TBA, and Hb showed moderate discrimination for suboptimal HBP imaging. These routinely available indicators may assist pre-MRI risk stratification, but external validation is required before clinical implementation.
Related
- Assessment of Liver Fibrosis Using the Coefficient of Variation on Gadoxetic Acid-Enhanced Hepatobiliary Phase MR Imaging: A Prospective Multicenter Study
- Development and Validation of an Interpretable Machine‐Learning Model for Predicting Suboptimal Clinical Response After Sleeve Gastrectomy: A Multicenter Study
- Multi-model comparison and nomogram development for predicting in-hospital mortality in Trauma patients based on NLR and other indicators
- Predicting the Risk of Distal Junctional Kyphosis After Surgery for Adolescent Idiopathic Scoliosis Using Preoperative Radiographic Indicators and Machine Learning
- Serum Cystatin 4 combined with routine clinical laboratory indicators: A support vector machine diagnostic model for early screening of gastrointestinal tumors
BibTeX
@article{qiu2026laboratory,
title = {{Laboratory indicators combined with liver function scores for predicting suboptimal hepatobiliary phase imaging during gadoxetic acid-enhanced MRI}},
author = {Fuhe Qiu and Fuling Huang and Haihui Pan and Jiancong Li and Feichen Lu},
journal = {Frontiers in Medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1945459},
url = {https://doi.org/10.3389/fmed.2026.1945459},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Laboratory indicators combined with liver function scores for predicting suboptimal hepatobiliary phase imaging during gadoxetic acid-enhanced MRI
AU - Fuhe Qiu
AU - Fuling Huang
AU - Haihui Pan
AU - Jiancong Li
AU - Feichen Lu
PY - 2026
DA - 2026/10/13
JO - Frontiers in Medicine
DO - 10.3389/fmed.2026.1945459
UR - https://doi.org/10.3389/fmed.2026.1945459
AB - Background: Suboptimal hepatobiliary-phase (HBP) enhancement may limit the diagnostic quality of gadoxetic acid-enhanced MRI. We investigated whether routinely available laboratory indicators and liver function scores could identify patients at increased risk of suboptimal HBP imaging. Methods: This retrospective study included 555 patients with focal liver lesions who underwent gadoxetic acid-enhanced MRI, including 460 with good and 95 with suboptimal HBP image quality. Associations between laboratory indicators, liver function scores, and HBP image quality were evaluated using correlation and logistic regression analyses. Model discrimination, calibration, internal validation, and potential clinical utility were assessed using ROC analysis, bootstrap resampling, calibration analysis, and decision-curve analysis. Results: The ALBI score (OR=2.391, 95% CI: 1.364–4.190), GGT (OR=1.003, 95% CI: 1.001–1.004), TBA (OR=1.010, 95% CI: 1.003–1.017), and Hb (OR=0.982, 95% CI: 0.971–0.993) were independently associated with suboptimal HBP imaging. The combined model yielded an AUC of 0.758 (95% CI: 0.701–0.816), with 63.16% sensitivity and 78.70% specificity. Bootstrap internal validation that repeated the entire model-development procedure yielded a mean AUC optimism of 0.044 and an optimism-corrected AUC of 0.714, indicating that moderate discrimination was retained after correction for model-development optimism. The apparent and optimism-corrected Brier scores were 0.116 and 0.128, respectively. Conclusions: A model combining the ALBI score, GGT, TBA, and Hb showed moderate discrimination for suboptimal HBP imaging. These routinely available indicators may assist pre-MRI risk stratification, but external validation is required before clinical implementation.
SN - 2296-858X
ER -